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Abstract
Background: Venous thromboembolism (VTE) in young children is not well documented.
Methods: Clinicians from 12 institutions retrospectively evaluated the presentation, therapeutic management, and
outcome of VTE in children younger than 2 years seen in 2011–2016. Feasibility of recruiting these children in
EINSTEIN-Jr. phase III, a randomized trial evaluating rivaroxaban versus standard anticoagulation for VTE, was assessed.
Results: We identified 346 children with VTE, of whom 227 (65.6%) had central venous catheter-related thrombosis
(CVC-VTE), 119 (34.4%) had non-CVC-VTE, and 156 (45.1%) were younger than 1 month. Of the 309 children who
received anticoagulant therapy, 86 (27.8%) had a short duration of therapy (i.e. < 6 weeks for CVC-VTE and < 3 months
for non-CVC-VTE) and 17 (5.5%) had recurrent VTE during anticoagulation (n = 8, 2.6%) or shortly after its
discontinuation (n = 9, 2.9%). A total of 37 (10.7%) children did not receive anticoagulant therapy and 4 (10.5%) had
recurrent VTE.
The average number of children aged < 0.5 years and 0.5–2 years who would have been considered for enrolment in
EINSTEIN-Jr is approximately 1.0 and 0.9 per year per site, respectively.
Conclusions: Young children with VTE most commonly have CVC-VTE and approximately one-tenth and one-fourth
received no or only short durations of anticoagulant therapy, respectively. Recurrent VTE rates without anticoagulation,
during anticoagulation or shortly after its discontinuation seem comparable to those observed in adults. Short and
flexible treatment durations could potentially increase recruitment in EINSTEIN-Jr. phase III.
Keywords: Venous thromboembolism (VTE), Pediatric trial, Rivaroxaban, Direct oral anticoagulant (DOAC/NOAC),
Anticoagulation, Registry
Background
Pediatric anticoagulant guidelines for venous thrombo-
embolism (VTE) are mainly based on extrapolation from
trials in adults, with low levels of evidence from the
pediatric population. However, anecdotal evidence in ne-
onates resulted in suggested (Grade 2 C recommenda-
tions) treatment durations of between 6 weeks and
3 months for both central venous catheter-related VTE
(CVC-VTE) and other VTE (e.g. renal vein thrombosis
or cerebral sinus venous thrombosis) [1]. In clinical
practice, shorter durations of treatment (i.e. < 3 months)
are frequently used in children beyond the neonatal age
group, presumably related to the difficulties in delivering
anticoagulation using currently available drugs.
Performing clinical studies in young children with
VTE is challenging for a variety of reasons. First, VTE is
a relatively rare condition in children with reported inci-
dences being approximately 100 times lower than in
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adults, requiring large and expensive collaborative efforts
to recruit even a low number of children [2–8]. Second,
young children with VTE represent a sick population since
their VTE is often hospital acquired, largely due to more
aggressive treatments of serious and life-threatening co-
morbidities [9]. Third, international restrictions on blood
volumes that can be drawn for purposes other than rou-
tine medical care, limit participation of those with a low
bodyweight [10]. Finally, parental consent is often difficult
to obtain in young children with acute serious conditions
in combination with a short decision window.
The EINSTEIN-Jr phase III study (clinicaltrials.gov
NCT02234843) is a randomized study comparing the ef-
ficacy and safety of bodyweight-adjusted rivaroxaban
with standard anticoagulation for the treatment of acute
VTE in children [11]. The study started in 2014 with
children aged 12–18 years and, in a staggered approach,
continued with those aged 6–12 years, and 2–6 years.
Study treatment is given for 3 months with the option to
continue treatment in 3 months increments, up to a
total duration of 12 months, with a repeat imaging test
scheduled at month 3. During the last phase of the
EINSTEIN-Jr. study, recruitment will be opened for neo-
nates and infants younger than 2 years.
In this retrospective analysis, we describe the presenta-
tion, therapeutic management, and outcomes observed in
children younger than 2 years who received care for VTE
in recent years. In addition, we assessed their potential eli-
gibility for enrolment into the EINSTEIN-Jr trial.
Methods
A group of EINSTEIN-Jr. investigators from 12 institu-
tions in North America, Europe and Israel collected data
from their institutions for the period 2011–2016 for chil-
dren younger than 2 years with VTE and described the
diagnosis of VTE at the time of presentation, if anti-
coagulant therapy was instituted, and the type of ther-
apy. In addition, they assessed if children had developed
recurrent VTE.
The potential eligibility for the EINSTEIN-Jr study of chil-
dren with VTE seen in 2016 was done by determining the
proportion of children who would have passed the screen of
inclusion and exclusion criteria, as proposed in the protocol
(Table 1). Then, investigators indicated whether or not they
would have considered each child for inclusion into the
study. This question was intended to capture additional fac-
tors not specified by the eligibility criteria, such as the child
being considered too ill, or because the child was discharged
to a remote location.
Data that was collected from the records included year
of diagnosis, site of venous thrombosis, gestational age
and bodyweight at birth, age at diagnosis, type of anti-
coagulant treatment (if given), and occurrence of recur-
rent VTE. For the purposes of this study, short duration
treatment was defined a priori as < 6 weeks for those
CVC-VTE and < 3 months for those with non-CVC-VTE.
In addition, other details available to address the set of eli-
gibility criteria were collected. To better describe factors
which may contribute to children being rendered ineli-
gible for participation in EINSTEIN-Jr, the cumulative loss
of children for the year 2016 is depicted in a funnel dia-
gram. For the latter analysis, children for whom missing
data was reported were assumed to have fulfilled criteria.
The search strategies to identify children with VTE
varied between the sites and consisted of review of antic-
oagulation prescription records from the hospital phar-
macy database, the investigator’s referral records,
discharge letters, and department’s patient records. At a
single site, data was collected for the first 2 months of
each year and, therefore, does not represent a complete
sample over the time period 2011–2016.
The study was conducted by Competitive Drug Devel-
opment International Ltd. (CDDI), London, United King-
dom in collaboration with Bayer AG. The protocol was
approved by the Institutional Review Board or Ethics
Committee of each participating center, when required.
Data handling
De-identified data was retrieved and entered into a vali-
dated electronic data capture system at the investigator
site and, once queries had been clarified, downloaded
into an Excel workbook. Results were calculated as
percentages.
Results
Patients
A total of 346 children younger than 2 years were identi-
fied of whom 227 (65.6%) had CVC-VTE and 119
(34.4%) had non-CVC-VTE (Table 2). The age distribu-
tion of these children is shown in Fig. 1. VTE was most
prevalent during the first months of life with 156
(45.1%) being younger than 1 month. Most children
were diagnosed with VTE in neonatal or pediatric inten-
sive or high care units (91% of children < 0.5 years and
67% of children aged 0.5–2 years). The most frequently
involved anatomical sites in the CVC-VTE group were
the extremities, caval vein or lungs (123, 54.2%), jugular
or subclavian vein (61, 26.9%), and the heart (24, 10.6%;
Table 2). The most frequently involved anatomical sites
in the non-CVC-VTE group were the cerebral veins and
sinuses (45, 37.8%), and extremities, caval vein or lungs
(27, 22.6%; Table 2).
Anticoagulant therapy
A total of 37 (10.7%) of the 346 children did not receive
anticoagulant treatment (Table 2). Of the 309 children
who had anticoagulant therapy, 282 (91.3%) received low
molecular weight heparin, 24 (7.8%) unfractionated
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heparin, 2 (0.6%) fondaparinux, and 1 (0.3%) received
only therapy with vitamin K antagonists, whereas 6
(1.9%) children transitioned from heparins to vitamin K
antagonists. Type of anticoagulant and treatment dura-
tions were similar for the various manifestations of ven-
ous thrombosis and across age groups (Tables 2 and 3).
Efficacy outcomes
Of the 309 children who received anticoagulation, 17
(5.5%) had a symptomatic recurrent VTE (Table 4),
which occurred during anticoagulation in 8 (2.6%;
CVC-VTE group, 6/199 (3.0%); non-CVC-VTE
group, 2/110 (1.8%)) and following discontinuation
of anticoagulation in 9 (2.9%; CVC-VTE group, 8/
199 (4.0%); non-CVC-VTE group, 1/110 (0.9%)). Of
the 37 children who were not treated with anticoag-
ulants, 4 (10.5%); had a recurrent VTE (all 4 were in
the CVC-VTE group, 4/28 (14.3%); non-CVC-group,
0/9 (0%)). Results were similar across age categories
(data not shown).
Table 1 Inclusion and exclusion criteria of the EINSTEIN Jr. study in children younger than 2 years as evaluated in this feasibility
assessment
Eligibility criteria Rationale
Inclusion criteria for children aged < 0.5 year
Confirmed VTE and initial treatment with therapeutic dosages of UFH,
LMWH or fondaparinux and requirement for anticoagulant therapy for at
least 3 months (at least 6 weeks for those with catheter-related VTE)
Target population
Gestational age at birth of at least 37 weeks Maturation of organs involved in rivaroxaban absorption and
clearance depend on the gestational and postnatal age.
Rivaroxaban PK variability is expected to be higher in children
born preterm compared to term neonates and older children
[15–21].
Oral, nasogastric or gastric feeding for at least 10 days Literature data indicates that gastrointestinal conditions are
more stable in children with a gestational age of ≥37 weeks
who have been on oral feeding for at least 10 days [15–21].
Rivaroxaban should be taken with food to achieve optimal
absorption [22, 23].
Bodyweight ≥2600 g Above 2600 g representative virtual children could be
simulated with the rivaroxaban PBPK model for (term born)
neonates
Inclusion criteria for children aged 0.5–2 years
Confirmed VTE and initial treatment with therapeutic dosages of UFH,
LMWH or fondaparinux and requirement for anticoagulant therapy for at
least 3 months (at least 6 weeks for those with catheter-related VTE)
Target population
Exclusion criteria
Active bleeding or bleeding risk contraindicating anticoagulant therapy Potential risk factor for (increased) bleeding with any
anticoagulant
Estimated glomerular filtration rate < 30 mL/min/1.73m2 (in children
< 1 year, serum creatinine results above 97.5th percentile [24, 25]
Potential risk factor for bleeding with any anticoagulant
Hepatic disease associated with either a coagulopathy leading to a
clinically relevant bleeding risk, or ALT > 5× ULN
Potential risk factor for bleeding with any anticoagulant
Platelet count < 50 × 109/L Potential risk factor for bleeding with any anticoagulant
Sustained uncontrolled hypertension defined as systolic and/or diastolic
blood pressure > 95th age percentile [26]
Potential risk factor for bleeding with any anticoagulant
Life expectancy < 3 months A priori likelihood for the child to not complete the study
Concomitant use of strong inhibitors of both CYP3A4 and P-gp; Potential for increased rivaroxaban plasma concentrations to
a clinically relevant degree
Concomitant use of strong inducers of CYP3A4 Potential for reduced rivaroxaban plasma concentrations
Gastrointestinal disease associated with impaired absorption Potential for reduced rivaroxaban plasma concentrations
Hypersensitivity or any other contraindication listed in the local labeling for
rivaroxaban or comparator treatment
Contraindication for use of the product
Participation in a study with an investigational drug or medical device
within 30 days prior to randomization
Regulatory requirement
VTE denotes venous thromboembolism, UFH unfractionated heparin, LMWH low molecular weight heparin, ALT alanine aminotransferase, ULN upper limit of
normal, CYP 3A4 cytochrome P450 isoenzyme 3A4, P-gp P-glycoprotein
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Table 2 Type of anticoagulant therapy given for children younger than 2 years diagnosed with VTE
Total population,
N = 346
Children aged
< 0.5 year, N = 271
Children aged
0.5-2 years, N = 75
CVC-VTE, n (%) 227 (65.6) 175 (64.6) 52 (69.3)
Anticoagulation,a n (%) 199 (88) 153 (87) 46 (88)
No anticoagulation, n (%) 28 (12) 22 (13) 6 (12)
Non-CVC-VTE, n (%) 119 (34.4) 96 (35.4) 23 (30.7)
Anticoagulation,a n (%) 110 (92) 88 (92) 22 (96)
No anticoagulation, n (%) 9 (8) 8 (8) 1 (4)
CVC-VTE
Extremity/caval vein thrombosis/pulmonary embolism 89 34
Anticoagulation,a n (%) 76 (85) 30 (88)
No anticoagulation, n (%) 13 (15) 4 (12)
Cardiac thrombosis 20 4
Anticoagulation,a n (%) 18 (90) 4 (100)
No anticoagulation, n (%) 2 (10) 0
Renal vein thrombosis 1 0
Anticoagulation,a n (%) 1 (100) –
No anticoagulation, n (%) 0 –
Portal vein thrombosis 18 0
Anticoagulation,a n (%) 14 (78) –
No anticoagulation, n (%) 4 (22) –
Jugular/subclavian vein thrombosis 47 14
Anticoagulation,a n (%) 44 (94) 12 (86)
No anticoagulation, n (%) 3 (6) 2 (14)
Non-CVC-VTE
Cerebral venous sinus thrombosis 37 8
Anticoagulation,a n (%) 34 (92) 8 (100)
No anticoagulation, n (%) 3 (8) 0
Extremity/caval vein thrombosis/pulmonary embolism 16 11
Anticoagulation,a n (%) 14 (88) 11 (100)
No anticoagulation, n (%) 2 (13) 0
Cardiac thrombosis 12 0
Anticoagulation,a n (%) 12 (100) –
No anticoagulation, n (%) 0 –
Renal vein thrombosisb 14 0
Anticoagulation,a n (%) 12 (86) –
No anticoagulation, n (%) 2 (14) –
Portal vein thrombosisb 14 1
Anticoagulation,a n (%) 14 (100) 0
No anticoagulation, n (%) 0 1 (100)
Jugular/subclavian vein thrombosis 4 3
Anticoagulation,a n (%) 3 (75) 3 (100)
No anticoagulation, n (%) 1 (25) 0
aUnfractionated heparin, low molecular weight heparin, fondaparinux or vitamin K antagonists. bA single patient had renal and portal vein thrombosis and was
therefore considered in both groups
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Reasons for ineligibility for EINSTEIN-Jr
The main reasons for ineligibility for children aged
< 0.5 years were a gestational age < 37 weeks (35.4%),
a bodyweight < 2600 g (25.4%), and inadequate oral,
nasogastric, or gastric feeding prior to or on the day
of their diagnosis of VTE (36.5%). Figure 2 shows
the percentage of children not meeting the
remaining individual inclusion and exclusion criteria
of the draft EINSTEIN-Jr protocol criteria. The main
reasons for ineligibility for the entire cohort of chil-
dren younger than 2 years, were no anticoagulant
therapy given (11%), duration of anticoagulant ther-
apy was too short (25%), presence of active bleeding
or high bleeding risk (20%), gastrointestinal disease
potentially associated with poor absorption (19%),
and use of potent CYP 3A4 inducers (13%).
Estimated cumulative loss of participation in EINSTEIN-Jr
For the year 2016, a total of 101 children (aged < 0.5 years)
and 35 children (aged 0.5–2 years) were evaluated using
the EINSTEIN-Jr eligibility criteria (Figs. 3 and 4). Of
these, 18 (17.8%) and 13 (37.1%) would have passed the
screen of eligibility criteria of EINSTEIN-Jr., of whom 12
(11.9%) and 11 (31.4%) would have been considered for
participation by the clinicians, respectively. This translates
into an average number of potentially eligible children per
year per site of 1.0 and 0.9, respectively. If a consent rate
of 50% is assumed, these numbers will be 0.5 and 0.5 chil-
dren per year per site, respectively.
Discussion
This study demonstrated that two-thirds of children
with VTE younger than 2 years developed their VTE as
a complication of the use of central catheters, with the
highest incidence of VTE in the first month of life. In
contradistinction to what might be expected given the
current pediatric anticoagulant guidelines [1], this snap-
shot of contemporary clinical practice revealed that no
anticoagulant therapy was given to one-tenth of chil-
dren, whereas one-fourth received a short duration of
anticoagulant therapy, respectively. Recurrent VTE rates
without anticoagulation, during anticoagulation or
shortly after its discontinuation seem comparable to
those observed in adults [27–30].
The reasons behind non-adherence to the international
guidelines for many children in this analysis was beyond
the scope of this study, however, it is likely that it is related
to the absence of any randomized, quasi-randomized, or
cluster-randomized controlled trials in neonates or young
children with a diagnosis of thrombosis [31]. In addition,
we postulate that it could be related to the presence of ser-
ious illnesses contraindicating the use of anticoagulants,
apprehension of bleeding risk in the neonatal period, the
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Fig. 1 Age of children younger than 2 years diagnosed in 2011–2016 (N = 346)
Table 3 Short durations of anticoagulant treatment in relation
to presenting VTE and age
Duration anticoagulation shorter than 6 weeks (CVC-VTE
group) or shorter than 3 months (non-CVC-VTE group)
Children aged
< 0.5 year (n = 241)
Children aged
0.5–2 years (n = 68)
CVC-VTE,
n = 199
36/153 (24) 8/46 (17)
Non-CVC-VTE,
n = 110
35/88 (40) 7/22 (32)
CVC-VTE denotes central venous catheter related venous thromboembolism
Table 4 Recurrent VTE in relation to presence or absence of
anticoagulant therapy
CVC-VTE Non-CVC-VTE
N = 227 N = 119
During anticoagulation, n/N (%) 6/199 (3.0) 2/110 (1.8)
Following discontinuation of
anticoagulants, n/N (%)
8/199 (4.0) 1/110 (0.9)
No anticoagulant group, n/N (%) 4/28 (14.3) 0/9 (0)
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presentation with minimal clots, and the practice of repeat
ultrasound imaging to guide duration of treatment, with
continuation of anticoagulation only if recanalization has
failed. Whether resolution on ultrasound represents true
cure, and abolition of risk of recurrence for catheter or
non-catheter related VTE remains to be determined.
The most important reasons which could render chil-
dren younger than 2 years ineligible for the EINSTEIN-Jr
study were a gestational age of less than 37 weeks at birth,
a bodyweight less than 2600 g and the requirement for at
least 10 days of oral feeding. As a result, an inclusion rate
of approximately 0.5 young child per year per site can be
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Fig. 2 Percentage of the whole population not meeting individual eligibility criteria of the draft EINSTEIN-Jr. protocol. The bars sum to more than
100% because many children would have been excluded by multiple criteria
Total number of children
Gestational age at birth 37 weeks
Oral feeding 10 days
Bodyweight 2600 g
Anticoagulant treatment
Duration of anticoagulation 6 weeks (for CVC) or 3 months (for non-CVC)
No active bleeding or bleeding risk
No gastrointestinal disease
eGFR 30 mL/min/1.73m2 or creatinine 1.5× normal
No hepatic disease
Platelet count 50× 109/L
No hypertension
Life expectancy 3 months
No strong inhibitors of CYP3A4 and P-gp
No strong inducers of CYP3A4
Not in another clinical study
Investigator would have offered participation
Potentially eligible children
Average number of children per site per year
Assuming a consent rate of 50%
101
71
44
41
39
28
24
23
22
21
21
21
21
21
18
18
12
12
1.0
0.5
Fig. 3 Funnel showing cumulative loss of children aged < 0.5 year due to failure to meet the proposed eligibility criteria. Missing data does not
exclude the individual
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anticipated in EINSTEN-Jr. Use of short and flexible treat-
ment durations carries potential to increase recruitment
rates and appears to be in keeping with current practice
for anticoagulant therapy duration, but raises the spectre
of elevating expected recurrence rates.
Based on this analysis, we did not modify the screen of
eligibility criteria of young children; however, we decided
that young children with CVC-VTE could be treated for a
minimum of 4 weeks. Although a treatment duration of
less than 3 months carried the potential for increased re-
cruitment in children younger than 2 years who had
non-CVC-VTE, we decided to keep the required treat-
ment durations at least 3 months since it is well docu-
mented that shorter periods of anticoagulation are
associated with increased rates of recurrent VTE in adults
[12–14]. We believe that these treatment durations will
allow physicians to consider most young children with
clinically significant VTE for our study. If physicians con-
sider prolongation of anticoagulation beyond these re-
quired durations, the protocol will allow continuation of
treatment for CVC-VTE in 1-month increments (up to a
total duration of 3 months), and continuation of treatment
for other VTE in 3-months increments (up to a total dur-
ation of 12 months). Also, repeated imaging will be done
at the end of the 1-month treatment period in children
with CVC-VTE and at the end of the 3-months treatment
period in children with other VTE.
Potential limitations
Due to the retrospective nature of the study, we believe that
our analysis may overestimate the eligibility for
EINSTEIN-Jr. of young children with VTE. Although a
large consecutive series of children diagnosed with VTE
was identified, the physician’s assessment of eligibility may
have overlooked conditions and circumstances which at the
time of the acute phase could have rendered the child ineli-
gible. Furthermore, our search strategy to identify children
with VTE may have been biased towards those who had re-
ceived anticoagulant therapy, thereby underestimating the
number of young children who did not receive anticoagu-
lant therapy. Also, we did not capture whether anticoagula-
tion was given in therapeutic dosages and it is, therefore,
possible that some of the considered children received
anticoagulation in sub-therapeutic dosages.
Conclusions
Neonates and young children with thrombosis often have
CVC-VTE, and often receive no or only short durations of
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Total number of children
Gestational age at birth ≥37 weeks
Oral feeding ≥10 days
Bodyweight ≥2600 g
Anticoagulant treatment
Duration of anticoagulation ≥6 weeks (for CVC) or ≥3 months (for non-CVC)
No active bleeding or bleeding risk
No gastrointestinal disease
eGFR ≥30 mL/min/1.73m2 or creatinine ≤1.5× normal
No hepatic disease
Platelet count ≥50× 109/L
No hypertension
Life expectancy ≥3 months
No strong inhibitors of CYP3A4 and P-gp
No strong inducers of CYP3A4
Not in another clinical study
Investigator would have offered participation
Potentially eligible children
Average number of children per site per year
Assuming a consent rate of 50%
Fig. 4 Funnel showing cumulative loss of children aged 0.5–2 years due to failure to meet the proposed eligibility criteria. Missing data does not
exclude the individual
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anticoagulant therapy. Recurrent VTE rates without antic-
oagulation, during anticoagulation or shortly after its dis-
continuation seem comparable to those observed in
adults. Longitudinal studies to better understand the nat-
ural history of VTE in young children are urgently re-
quired. Once the population that definitely requires
treatment is identified, then randomized clinical trials
evaluating anticoagulant strategies are urgently needed to
address the question of dose and duration, and to evaluate
its benefit/risk in the treatment of VTE in young children.
However, recruitment will be very challenging. Allowing
short and flexible treatment durations into the
EINSTEIN-Jr. phase III study could potentially increase
recruitment and permit a representative population of
current practice.
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